Member Info for fastduckharry

Presumably Haydale believe they have cracked this problem and that this money will be spent testing their solution in the reality of manufacturing tanks with their coated steel.

Have no doubt that when it comes to scientific skillls that Haydale are well equipped to come up with the goods. I just hope that they also have people with enough commercial nowse, To ensure that Haydale are amply rewarded for their solutions with regards to patents and licensing.

Therefore not getting carried away but do regard this as a very promising development. As it could lead to the sale of Plasma Reactors at £2m+ each to produce the required nano materials and royalties on each tank produced. All very much in the future at this stage.

Rooky, am exploring this company, not holding any. From looking at recent results the US payments business is striding ahead whilst the UK's seems to be more affected by Covid-19. What this rns is not telling me, whilst looking good, is how the UK is faring.

Obviously there is the TFL congestion zone payments 6 year contract extension announced in August. The expansion of the zone, when congestion has probably reduced due to working from home, introduces political uncertainty with elections due. Anything else of significance? The UK has had a higher profit margin than the US, therefore more decline could impact the bottom line.

I will be looking for information come the Trading Update in May, if no news before. Good luck.

dcr, many thanks in your efforts in attracting interest in this company. Am a long term holder having bought in near the lows of the great crash. My thinking then was that the otc business would contribute towards the costs of drug development, hence reducing the investment risk. That part of the company has now been sold but only after helping HCM to grow to the valuation it has today. Being able to raise capital without massive dilution of the shareholder base is a huge plus.

Many analysts look at drug sales x 20 as a basis for valuation. With the otc business numbers being removed. It does not look as good, though that does not account for the fact that HCM is still a young company with a large development pipeline. From my unqualified perspective, it would seem that HCM is likely to be achieving a proper valuation around 2026/27 and perhaps starting to pay a dividend. Not only that but still regarded as a growing company.

It is not a company for day traders. I see the people investing in HCM now, are those who have a good income with plenty of capital for investment. What they don't have is the time to be keeping a very regular eye on their holdings. Or indeed worry about short term rotational share price movements. There is some risk but the likely return in growth, certainly justifies some investment for those patient enough to hold. Obviously, in an investment vehicle that protects capital gains from the taxman.

Am not going to be posting here regularly, perhaps next time in 2026, god willing. Will still be holding HCM but now intending to diversify my portfolio as a hobby. Wish you all good luck and health - fdh.

Hopefully the money generated will be used to increase GBG's AI/biometric offering, whether it be by acquisition or by in-house development.

Yesterday was a start. With most of the financial information already being out there, it was a penalty kick for the day traders.
Regarding yesterday's RNS, strategy featured 3 times and strategic 12 times. They laid out what they are doing going forward, now they have to achieve and more. That means not only gaining new business but also improving the offering to retain customers, technology does not stand still.

Cautious investors both institutional and private, looking to hold long term, will be waiting for the next trading update, likely in July. Even then if the news is good, many will still put that down to the effects of the CoViD-19 pandemic. Assuming the vaccine rollouts have succeeded, the probability is that H2-21 performance will be a key factor in deciding the future prospects of LoopUp with regard to the SP.

I can't cope with the daily stress of looking at share prices and reading share chat, not that it isn't informative at times. Firstly it is time consuming and more importantly it can lead to bad investing decisions. Own a stock, don't let it own you. That is why am not Premium, have been there. If I can't trust a company to deliver long term, do not want to hold. Will keep LOOP, at least till July's update. If that is promising, there is H2 and who knows. Have an interest in 20 stocks, am currently examining them all for future prospects, with a view to focusing on 5 for the next few years.

Wishing you all a good end of lockdown and successful investing.

I read the Interim Results rns again. It is striking how bullish BeeksFC are. From the report, the words of CEO Gordon McArthur to digest are:

"we are confident that Beeks is poised for considerable growth within a rapidly developing market."

Am getting up to speed with Haydale. They make the nano-materials for CeramycShield but don't own. The patent owner and product manufacturer is Zirconia, an American company based in Washington State, north of Tacoma.

Haydale agreed a 30 month distribution agreement for the product (rns 20 July 2020), in the UK Water infrastructure market but able to distribute in other areas of the World with Zirconia's permission. As it happens, Biwater, who have had a successful trial of CeramycShield in Nicaragua, are a UK company but with many regional offices around the World. This agreement is extendable. It also provides for Haydale and Zirconia, to work to develop jointly owned intellectual property for next generation products applicable across multiple global infrastructure markets. I appreciate most holders of HAYD were already aware of this.

On the back of the successful Biwater Trial, I would expect this agreement to be extended providing this converts to orders.

Ian.B Many thanks for that information. As I understand it, once a position is under 5% there is no requirement to report a change in holdings. Though would not make sense to sell at the current oversold SP.

Am in here because of the apparent value in LOOP. Tomorrow's results and forward looking statements will no doubt deliver some cautious price targets in the next few weeks. Am interested in LOOP's strategy in going forward from here. Have an interest in GAMA who are now expanding into Europe. A regional partner agreement with their German, Spanish subsidiaries could be beneficial, perhaps?

I bought my first batch of Loop a couple of weeks ago and topped up again last week. It has been an interesting few days.

I find it odd that the SP fell from £2.40 in October down to £1.51 in November before the Nov 27 Trading Update came out. Simon Thompson of IC thought they were still a buy in late Sept @£2.45. Analysts were predicting as much as £4.24

The fall in non professional usage should have been predicted by analysts in view of other services being available when audio quality was not a critical requirement for everybody. That said the fall in the SP has been overdone, it should be over a pound. I understand now though, why people are anxious/nervous about next Tuesday's Results announcement and what else it may contain.

Suggestions that Covid-19 variants could be around for the next years should help to underpin the business model, when it comes to professional usage. The threat of Microsoft squeezing out Loopup with a similar high level service is a slight worry. What does Partner actually mean? More likely they will just make an offer for Loopup hopefully @1.50 or thereabouts, after the SP has already climbed up to £1.20. Do you think the Bod would recommend or hold out for more? I would take the money at that price, how about you?

Had a look at the project, involving the waste water treatment plant in Managua Nicaragua, where this trial is taking place, on the Biwater website. The trial is the coating of just one primary clarifier at this particular plant. There are in fact nine. Also in recognition of Biwater's good management of the site they have received extensions to Operation and Management contracts not just at this site but at other neighbouring plants as well. Primary clarifiers are designed to remove much, usually around 60%, of the solids in the water. The drop to the floor of the tank and form a sludge which needs to be removed regularly. Problems arise due to the permeable nature of untreated concrete, with regard to contaminants and bacteria.

In view of the success of the CeramycShield coating here, the prospect of further use of this product by Biwater is extremely high. We are not talking about just Nicaragua but the many thousands of primary clarifiers across the World.

From a green perspective, this is likely to mean the lifetime of these concrete structures extended. Also preventing contamination and bacteria build up in these clarifiers. The water released is going to be cleaner. Which is to the benefit of wildlife.

Haydale state that CeramycShield is manufactured as a complete product in the USA. However, I imagine that the manufacture of the nano particle ingredients is done by Haydale, in order to protect their IP. Can anybody confirm this? The potential of just this product alone, not just in waste water treatment, is going to demand an increase in manufacturing capability. This links to Friday's news of an agreed loan of £1.1m, to do just that. Some could quibble with the interest rate of 7.5% which actually does not apply until all the money is drawn down. The tight schedule outlined in that rns suggests that Haydale are well advanced in terms of preparing for this expansion project. Money could have been raised by the issue of new shares. The resulting dilution at current low SP would no doubt prove to be a much more expensive option in the long term. Whereas expansion driven by orders is going to drive up the SP, to the benefit of all current shareholders.

At this stage, am not going to encourage anybody to buy more shares. I intend to hold onto mine, whilst waiting for more news from Haydale.

Have a few IPO, therefore was interested enough to investigate DNL on the back of this news. Needless to say have bought some. IPO look to be on to another real winner with this one. The company is well funded with no debt. A pipeline of products in trials means not yet in profit despite the success of first. This second product is likely to put that objective extremely close, with another likely to follow soon. This is without US approval, which is going to take longer but will come in a few years as the products are working. Somebody has kindly put up a link to research on DNL which puts a fair value of £2.40+ per share.

Yrab, this thread was started by somebody, who last Sept, had no idea why the sp wasn't back to £5 and later last Autumn was predicting £3 by Feb. That is the excitement I was thinking of.

If the future is looking bright for LoopUp, am sure the directors will be keen to buy shares and/or get options awarded after Tuesday's Results announcement. I'll leave the excitement to the rampers.

Thanks for the info.

SP moving upwards this morning with a number of buys. Perhaps news of a deal coming.

Sir Chris Evans founding CEO of Excalibur has written an article for today's The Times Red Box section advocating take up of their LFT with Sensyne MagnifEye. Article can also be read on Excalibur's website - news.

More detail of the Excalibur-Sensyne agreement in the SENS rns of 9 Feb 2021. Excalibur guaranteeing Sensyne, minimum revenues of £4.8m over two years. Current LFT manufacturing capacity of 1 billion per annum. The collaboration extends much deeper as Excalibur are working on Cancer testing LFTs utilizing MagnifEye technology.

I understand it as the latter option. As you say all will be clear in time. The Government will be wanting a ready made working solution for opening up. Isn't it some fans at sports events in mid-April?

Excalibur are claiming that combining their test with Sensyne's MagnifEye algorithm technology has made it more accurate. Sensyne had developed this technology to work with all LFTs. Excalibur are claiming an exclusive agreement. That would suggest that both companies are happy that their package could dominate the market in terms of testing for opening sport, entertainment and leisure business etc. If Sensyne's share per test was 50p, the potential revenues could well be running into the tens of millions. If the pilot has been a success and they get Government backing, a rns would most likely be issued. The share price would rocket then, for now it is just a gamble. Personally would be happy if the Government liked the Sensyne technology more and insisted it should be available for use with any LFTs they approve. With automatic infection data collected to the cloud it would be a huge boost for PHE to obtain access, for a fee. A fee being cheaper than expensive bureaucracy.

Calnex was founded in 2006 by Tommy Cook. It only listed as a plc, for the first time, last year.

The founder is still there and still hungry to expand the business. From reading the Herald Scotland 'accidental entrepreneur' article There is money for acquisition up to around £5m. In case of a bigger opportunity, he is prepared raise money from the markets to take advantage. That is why I am invested.

Am not on an expert but I think the key to the delay in releasing the results lies in the other rns today regarding Panmure Gordon, as nominated broker and sole corporate advisor. No more Numis, which suggests that Loopup have been put in a difficult position due to bad corporate advice.

As Loopup have said, nothing to do with money. Am not going to worry, if they fall further am inclined to top up.